Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Table 1
Baseline demographics and clinical characteristics.
All Patients
Risk Category at Initial MM Diagnosis
High Risk
Standard Risk
Unknown Risk
n
n
n
n
All patients, n ()
200
100.0
55
100.0
113
100.0
32
100.0
Age (years) at initial MM diagnosis
Mean (SD)
64.5
9.2
62.9
10.6
64.5
8.3
67.1
9.5
< 65 years, n (%)
103
51.5
33
60.0
54
47.8
16
50.0
≥ 65 years, n (%)
97
48.5
22
40.0
59
52.2
16
50.0
Age (years) at RRMM diagnosis
Mean (SD)
66.3
8.9
64.4
10.5
66.6
7.9
68.7
9.1
< 65 years, n (%)
85
42.5
31
56.4
45
39.8
9
28.1
≥ 65 years, n (%)
115
57.5
24
43.6
68
60.2
23
71.9
Sex, n ()
Male
123
61.5
33
60.0
74
65.5
16
50.0
Female
77
38.5
22
40.0
39
34.5
16
50.0
ISS stage at initial MM diagnosis, n ()
Stage I
26
13.0
4
7.3
14
12.4
8
25.0
Stage II
81
40.5
19
34.6
53
46.9
9
28.1
Stage III
88
44.0
31
56.4
42
37.2
15
46.9
Unknown
5
2.5
1
1.8
4
3.5
—
—
Impaired renal function, n (%)
12
6.0
6
10.9
4
3.5
2
6.3
Received stem cell transplant as part of first-line (induction) therapy, n ()
Autologous SCT
68
34.0
19
34.6
40
35.4
9
28.1
Tandem (double) autologous SCT
13
6.5
1
1.8
8
7.1
4
12.5
SCT not received
119
59.5
35
63.6
65
57.5
19
59.4
First-line (induction) systemic treatment regimens, n ()
Bortezomib + dexamethasone
55
27.5
7
12.7
37
32.7
11
34.4
Bortezomib + thalidomide + dexamethasone
27
13.5
13
23.6
11
9.7
3
9.4
Melphalan + prednisone + bortezomib
26
13.0
8
14.6
14
12.4
4
12.5
Melphalan + prednisone + thalidomide
24
12.0
6
10.9
12
10.6
6
18.8
Vincristine + doxorubicin + dexamethasone
18
9.0
1
1.8
14
12.4
3
9.4
Melphalan + prednisone
14
7.0
5
9.1
9
8.0
—
—
Bortezomib + cyclophosphamide + dexamethasone
12
6.0
8
14.6
3
2.7
1
3.1
Other induction regimens with frequency of <5 patients
24
12.0
7
12.7
13
11.5
4
12.5
Vital status at chart abstraction date, n ()
Alive
101
50.5
20
36.4
72
63.7
9
28.1
Deceased
99
49.5
35
63.6
41
36.3
23
71.9
Duration (months) of follow-up, from RRMM diagnosis to death/last available medical record, median
52
38
53
32
SCT = stem cell transplant, SD = standard deviation, and ISS = International Staging System. High risk: gene rearrangements del(17p), t(4;14), or t(14;16). Standard risk: all patients with known cytogenetics not classified as high risk. Unknown risk: patients with unknown cytogenetics. Stage I: serum β2-microglobulin < 3.5 mg/L and serum albumin ≥ 3.5 g/dL. Stage II: not stage I or III. Stage III: serum β2-microglobulin ≥ 5.5 mg/L.
